article thumbnail

Biotech R&D Platform Benchling Closes $100M at $6B Valuation

HIT Consultant

Benchling’s growth is fueled by the rapid rise of biotechnology , one of the world’s fastest-growing industries. As biotechnology companies come under increased pressure to deliver breakthroughs, they are turning to modern software to digitize all their scientific processes and centralize their data. Recent Traction/Milestones.

article thumbnail

Bioethics, Psychedelic Therapy Abuse, and the Risk of Ethics Washing

Bill Of Health

Although Grossbard and Bourzat deny the allegations, these accounts were vetted by leading news organizations, withstood legal threats from Grossbard and Bourzat, and have been substantiated by a growing body of consistent and corroborated accounts by survivors.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Healthcare & Life Science M&A Activity Plummets 1H’22

HIT Consultant

– The larger transactions in the quarter were, once again, transactions occurring in the Pharmaceutical and Biotechnology subsectors. . – Overall transaction value of deals announced and/or closed in Q2 2022 was $26 billion versus $31 billion in Q2 2021 and $65 billion in Q4 2021.

article thumbnail

Mitigating Serious Fall Risks and Associated Costs and Injuries with AI-Driven Motion Sensor Technology

HIT Consultant

According to a study in the Journal of the American Geriatric Society , non-fatal falls cost an estimated $50 billion in medical expenses, while fatal falls account for an estimated $754 million. It is also an expensive problem.

article thumbnail

Protecting the Consumer at the Heart of DTC Precision Medicine

Bill Of Health

To illustrate the issue, consider that the Privacy Rule of the Health Insurance Portability and Accountability Act (HIPAA) expressly covers genetic information as a form of health data. The innovation-security tradeoff is a familiar trope in biotechnology, but the main character of the direct-to-consumer tissue-based service story is less so.

article thumbnail

Why Congress should not mandate disclosure of drug development costs

Healthcare ECONOMIST

It may appear on financial statements that successful pharmaceutical make outsized profits, but these figures must also take into account that many pharmaceutical firms have drugs that fail and the companies go out of business. The bigger issue, however, is that of survival bias. Information on cost can promote innovation.

article thumbnail

Correctional Sleep: Where Litigation Falls Short and Where Research, Policymaking are Needed

Bill Of Health

So while typical mitigation strategies including correctional vaccination campaigns and social distancing remain necessary, effective correctional pandemic mitigations strategies must also account for poor sleep. To address the paucity of sleep research in U.S. Jolin is an A.B.